SCHEMBL7147453

SCHEMBL7147453

COc1ccc(C(=O)Nc2ccc(F)cc2)cc1Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.61
POLB P06746 1/20 0.59
ABL1 P00519 1/20 0.57
BCR P11274 1/20 0.57
KDR P35968 1/20 0.53
MAPT P10636 2/20 0.53
LMNA P02545 2/20 0.52
TP53 P04637 1/20 0.52
MPO P05164 2/20 0.52
PLG P00747 1/20 0.52
PLAU P00749 1/20 0.52
PLAT P00750 1/20 0.52
LCK P06239 1/20 0.52
KIT P10721 1/20 0.52
SRC P12931 1/20 0.52
MAPK14 Q16539 1/20 0.52
PIKFYVE Q9Y2I7 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152098 0.93 RXFP1 (0.65) RXFP1POLBABL1BCRMAPT
SCHEMBL7154124 0.90 RXFP1 (0.59) RXFP1POLBABL1BCRMAPT
SCHEMBL7150500 0.90 RXFP1 (0.54) RXFP1POLBMAPTLMNAMPO
SCHEMBL7147510 0.87 RXFP1 (0.58) RXFP1POLBABL1BCRMAPT
SCHEMBL7150180 0.87 RXFP1 (0.60) RXFP1POLBABL1BCRMAPT
SCHEMBL7155125 0.86 KMT2A (0.69) POLBMAPTLMNAMEN1KMT2A
SCHEMBL7152146 0.86 KMT2A (0.69) POLBMAPTLMNAMEN1KMT2A
SCHEMBL7149336 0.85 KMT2A (0.60) POLBMAPTLMNAMEN1KMT2A
SCHEMBL7152016 0.85 ABL1 (0.71) RXFP1ABL1BCRKDRLMNA
SCHEMBL7154469 0.85 POLB (0.61) RXFP1POLBABL1BCRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US claimed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US claimed
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US disclosed
US-6268387-B1 INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. WARNER-LAMBERT COMPANY 2001-07-31 US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 EP disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS RXFP1 2130/4885POLB 2441/4885ABL1 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.